Browsing: Puts

The race to treat obesity and diabetes is shifting again after Eli Lilly pushed back approval plans for its next-generation obesity drug, retatrutide, to Q1 2027, even as phase 3 data showed weight loss of up to 22.6% and blood sugar benefits. This mix of regulatory delay and clinical progress can reshape expectations for companies…

The race to reshape obesity and diabetes treatment is moving beyond weekly injections, and Vivani Medical’s long-acting GLP-1 implant has pushed that story into the spotlight. For investors, the question is how this kind of delivery shift might affect companies tied to GLP-1 drugs, devices, and support therapies. This article looks at 3 stocks from…